©TheCanadian Journal ofUrology™: International Supplement, April 2014
28.HandrattaVD,VasaitisTS,NjarVCetal.NovelC-17-heteroaryl
steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro
biologicalactivity,pharmacokinetics,andantitumoractivity in
theLAPC4humanprostatecancerxenograftmodel.
JMedChem
2005;48(8):2972-2984.
29.Vasaitis T, BelosayA, SchayowitzA et al. Androgen receptor
inactivation contributes to antitumor efficacy of 17{alpha}-
hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-
benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
Mol CancerTher
2008;7(8):2348-2357.
30.BrunoRD,VasaitisTS,GediyaLKetal.Synthesisandbiological
evaluationsofputativemetabolicallystableanalogsofVN/124-1
(TOK-001): head to head anti-tumor efficacy evaluation
of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human
prostatecancerxenograftmodel.
Steroids
2011;76(12):1268-1279.
31.MontgomeryRB, E.M.A, RettigM et al. , Phase I clinical trial
of galeterone (TOK-001), amultifunctional antiandrogen and
CYP17 inhibitor incastration resistantprostatecancer (CRPC).
J ClinOncol
2012;(suppl; abstr 4665).
32.Purushottamachar P et al. Systematic structuremodifications
of multitarget prostate cancer drug candidate galeterone to
produce novel androgen receptor down-regulating agents
as an approach to treatment of advanced prostate cancer.
JMedChem
2013;56(12):4880-4898.
33.Zellweger T, Kiyama S, Chi K et al. Overexpression of the
cytoprotective protein clusterin decreases radiosensitivity in
thehumanLNCaPprostate tumourmodel.
BJU Int
2003;92(4):
463-469.
34.Park DC, Yeo SG, WilsonMR et al. Clusterin interacts with
Paclitaxel and confer Paclitaxel resistance in ovarian cancer.
Neoplasia
2008;10(9):964-972.
35.Zellweger T, MiyakeH, Cooper S et al. Antitumor activity of
antisense clusterin oligonucleotides is improved in vitro and
in vivo by incorporation of 2’-O-(2-methoxy)ethyl chemistry.
J Pharmacol ExpTher
2001;298(3):934-940.
36.GleaveME, Monia BP, Antisense therapy for cancer.
Nat Rev
Cancer
2005;5(6):468-479.
37.Chi KN, Hotte SJ, Yu EY et al. Randomized phase II study of
docetaxelandprednisonewithorwithoutOGX-011 inpatients
withmetastaticcastration-resistantprostatecancer.
JClinOncol
2010;28(27):4247-4254.
38.ZoubeidiA, ZardanA,WiedmannRM et al. Hsp27 promotes
insulin-likegrowth factor-Isurvivalsignaling inprostatecancer
via p90Rsk-dependent phosphorylation and inactivation of
BAD.
CancerRes
2010;70(6):2307-2317.
39.GarridoC, FromentinA, Bonnotte B et al. Heat shockprotein
27 enhances the tumorigenicity of immunogenic rat colon
carcinoma cell clones.
CancerRes
1998;58(23):5495-5499.
40.ParcellierA,SchmittE,GurbuxaniSetal.HSP27 isaubiquitin-
binding protein involved in I-kappaBalpha proteasomal
degradation.
Mol Cell Biol
2003;23(16):5790-5802.
41.ZoubeidiA, ZardanA, Beraldi E et al. Cooperative interactions
between androgen receptor (AR) and heat-shock protein
27 facilitateAR transcriptional activity.
Cancer Res
2007;67(21):
10455-10465.
42.Chi KN, Hotte SJ, Ellard S et al.A randomizedphase II study
ofOGX-427plusprednisone (P)versusPalone inpatients (pts)
with metastatic castration resistant prostate cancer (CRPC).
J ClinOncol
2012;(suppl; abstr 4514).
43.Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T
immunotherapy for castration-resistant prostate cancer.
NEngl JMed
2010;363(5):411-422.
44.Longo DL. New therapies for castration-resistant prostate
cancer.
NEngl JMed
2010;363(5):479-481.
45.NabhanC.Sipuleucel-T immunotherapy forcastration-resistant
prostate cancer.
NEngl JMed
2010;363(20):1966-1967.
46.MayKFJr,GulleyJL,DrakeCG,DranoffG,KantoffPW.Prostate
cancer immunotherapy.
ClinCancerRes
2011;17(16):5233-5238.
47.Madan RA, Arlen PM, MohebtashM, Hodge JW, Gulley JL.
Prostvac-VF: a vector-basedvaccine targetingPSA inprostate
cancer.
ExpertOpin InvestigDrugs
2009;18(7):1001-1011.
48.Kantoff PW et al. Overall survival analysis of a phase II
randomized controlled trial of a Poxviral-basedPSA-targeted
immunotherapy in metastatic castration-resistant prostate
cancer.
JClinOncol
2010;28(7):1099-1105.
49.Hodi FS, O’Day SJ, McDermott DF et al. Improved survival
with ipilimumab inpatientswithmetastaticmelanoma.
NEngl
JMed
2010;363(8):711-723.
50.van den Eertwegh AJ, Versluis J, van den Berg HP et al.
Combined immunotherapy with granulocyte-macrophage
colony-stimulating factor-transducedallogeneicprostatecancer
cells and ipilimumab in patients with metastatic castration-
resistantprostate cancer: aphase1dose-escalation trial.
Lancet
Oncol
2012;13(5):509-517.
51.MadanRA, MohebtashM, Arlen PM et al. Ipilimumab and a
poxviralvaccine targetingprostate-specificantigen inmetastatic
castration-resistant prostate cancer: a phase 1 dose-escalation
trial.
LancetOncol
2012;13(5):501-508.
52.BeerTM,SlovinSF,HiganoCSetal.Phase I trialof ipilimumab
(IPI) alone and in combination with radiotherapy (XRT) in
patients with metastatic castration resistant prostate cancer
(mCRPC).
JClinOncol
2008;26(Suppl):abstract 5004.
53.Slovin SF, Higano CS et al. Initial phase II experience of
ipilimumab (IPI) alone and in combinationwith radiotherapy
(XRT) in patientswithmetastatic castration-resistant prostate
cancer (mCRPC).
JClinOncol
2009;27 (Suppl):15s,abstract5138.
54.Bristol-Myers Squibb Reports Results for Phase 3 Trial of
Yervoy® (Ipilimumab) in Previously-Treated Castration-
Resistant Prostate Cancer.
news/home/20130912005468/en/Bristol-Myers-Squibb-
Reports-Results-Phase-3-Trial.AccessedSeptember 12, 2013.
55.DrakeCG,GerritsenWR.Resultsof subset analysesonoverall
survival (OS) from studyCA184-043: Ipilimumab (Ipi) versus
placebo (Pbo) inpost-docetaxelmetastatic castration-resistant
prostatecancer (mCRPC).
JClinOncol
2014;32(Suppl4):abstr2.
56.MotzerRJ,HutsonTE,TomczakPetal.Overallsurvivalandupdated
results for sunitinib comparedwith interferon alfa in patients
withmetastatic renal cell carcinoma.
J Clin Oncol
2009;27(22):
3584-3590.
57.Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab
plus interferon alfa-2a for treatment of metastatic renal cell
carcinoma: a randomised, double-blind phase III trial.
Lancet
2007;370(9605):2103-2111.
58.Elisei R, Schlumberger MJ, Müller SP et al. Cabozantinib in
progressivemedullary thyroid cancer.
J ClinOncol
2013;31(29):
3639-3646.
59.SmithDC,SmithMR,SweeneyCetal.Cabozantinib inpatients
withadvancedprostatecancer: resultsofaphase IIrandomized
discontinuation trial.
JClinOncol
2013;31(4):412-419.
60.Finlay IG, Mason MD, Shelley M. Radioisotopes for the
palliationofmetastaticbonecancer:asystematicreview.
Lancet
Oncol
2005;6(6):392-400.
61.NilssonS,FranzénL,ParkerCetal.Bone-targetedradium-223 in
symptomatic,hormone-refractoryprostatecancer:arandomised,
multicentre,placebo-controlledphaseIIstudy.
LancetOncol
2007;
8(7):587-594.
62.ParkerC,NilssonS,HeinrichDetal.Alphaemitterradium-223
and survival inmetastatic prostate cancer.
NEngl JMed
2013;
369(3):213-223.
105
ThoresonETAL.
